Johnson & Johnson has completed its acquisition of Actelion, a company that develops pulmonary hypertension therapies, six months after the …
Maria Verissimo, MSc
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.